ALNYALNYLAM PHARMACEUTICALS, INC.
Health Care
Net Cash Provided by (Used in) Operating Activities revised down 15.0% for Q3 2025
This is the 10th largest revision in ALNY's history.
Net Cash Provided by (Used in) Operating Activities·Q3 2025
Major restatement$306.4M▼ 15.0%
was$360.5M
Revised down in a 10-Q. Any P/OCF built on the original was 17.7% too low.
No amendment filed
As reported · Oct 30, 202510-Q · Oct 29, 2026us-gaap:NetCashProvidedByUsedInOperatingActivitiesVerify against SEC filingsShow
As reported$360.5M
Accepted 2025-10-300001628280-25-047345
Restated$306.4M
Accepted 2026-10-290001178670-26-000076
OperatingCashFlow · reported 2 times · point-in-time, survivorship-free. Every figure traces to its filing above.
Track this the moment it happens
Get a signal the next time ALNY — or any company on your watchlist — restates a number. Every signal lands with the diff and its source filing.